Raw Wholesale Peptides, measured separately

A belly-fat result measured in square centimetres

The number I want to start with is -42 cm². In a 6-month trial involving 50 adults with HIV taking antiretroviral treatment, that was tesamorelin’s treatment effect on visceral fat compared with placebo. Visceral fat is the fat around the internal abdominal organs. The unit records an area inside the belly; it says nothing by itself about kilograms lost on a bathroom scale.

That exact square-centimetre unit is wonderfully inconvenient. “Fat loss” sounds like a single thing until a paper makes us ask where the fat was, how it was measured and whose body it came from. The same trial measured liver fat as well. There is a real, specific finding here, with a much more interesting shape than the broad claim.

Tesamorelin’s FDA-approved use concerns excess abdominal fat in adults with HIV-associated lipodystrophy, an unusual distribution of body fat. General weight loss falls outside that approval. The tesamorelin page follows the scan result through to the longer trial and the return of fat after treatment stopped.

Three compounds, three different questions

The wholesale name invites a big bundle. I distrust the all-purpose bundle: research on fat-making enzymes, body weight and muscle performance loses its meaning when it all gets called a metabolic benefit.

Consider AOD-9604. Obese mice used more fat as fuel and lost weight. Human obesity trials then failed to establish statistically significant weight loss versus placebo. The report covering roughly six trials and about 900 adults describes tolerability resembling placebo. For a weight-loss claim, the failed human endpoint deserves greater authority than an elegant account of mouse fat metabolism.

MOTS-c raises a different sort of curiosity. In mice, extra MOTS-c improved running capacity, grip strength and gait. Its origin in mitochondrial DNA and its movements inside cells make the biology unusually absorbing. Human treatment benefit remains unestablished; the human blood study discussed here measured a peptide already circulating in dialysis patients.

Those are different research histories. Their common presence in a discussion about peptides supplies no common measure of success.

The measurement I would add

Tesamorelin’s follow-up after stopping is my other preoccupation. In the 52-week programme, visceral fat returned after discontinuation. A smaller scan measurement has a duration attached to it.

The AOD-9604 claim has to clear the human weight-loss endpoint before it convinces me. For MOTS-c, a controlled human treatment trial measuring both benefit and harm would change the conversation far more than another appealing account of its activity inside cells. These judgments reflect the different stages the compounds have reached.

The comparison of measurements puts each outcome beside its population and time frame. The reading list includes the original papers, the safety reports and the reviews. There is plenty to be curious about without putting every finding into the same sack.